The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients

Author:

Louw Elizabeth1ORCID,Baines Nicola1,Maarman Gerald2,Osman Muhammad34ORCID,Sigwadhi Lovemore56,Irusen Elvis1,Koegelenberg Coenraad1,Doubell Anton7,Nathan Steven8,Channick Richard9,Allwood Brian1

Affiliation:

1. Division of Pulmonology, Department of Medicine Stellenbosch University & Tygerberg Hospital Cape Town South Africa

2. Division of Medical Physiology, Department of Biomedical Sciences, CARMA: Centre for Cardio‐Metabolic Research in Africa, Faculty of Medicine & Health Sciences Stellenbosch University Stellenbosch South Africa

3. Department of Paediatrics and Child Health, Desmond Tutu TB Centre Stellenbosch University Cape Town South Africa

4. Public Health, School of Human Sciences University of Greenwich London UK

5. Division of Epidemiology and Biostatistics Stellenbosch University Stellenbosch South Africa

6. Division of Statistics Biomedical Research and Training Institute, Zimbabwe Harare Zimbabwe

7. Division of Cardiology, Department of Medicine Stellenbosch University & Tygerberg Hospital Cape Town South Africa

8. The Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA

9. Pulmonary and Critical Care Division David Geffen School of Medicine Los Angeles California USA

Abstract

AbstractThere are an estimated 155 million survivors of tuberculosis (TB). Clinical experience suggests that post tuberculosis lung disease (PTLD) is an important cause of Group 3 pulmonary hypertension (PH). However, TB is not listed as a cause of PH in most guidelines. A cross‐sectional, community‐based study was conducted in nonhealthcare seeking adults who had successfully completed TB treatment. Subjects underwent questionnaires, spirometry, a 6‐min walk distance test (6MWD) and transthoracic echocardiography (TTE). Screen probable PH was defined on TTE as an estimated pulmonary artery peak systolic pressure (PASP) of ≥40 mmHg. One hundred adults (71 males) were enrolled, with a mean age of 42 years (SD 13.8 years) and a median of one TB episode (interquartile range: 1–2). Co‐morbidities included hypertension (21%), diabetes (16%), human immunodeficiency virus (10%) and asthma/COPD (5%). Only 25% had no residual symptoms after TB. Probable PH was found in 9%, while 7% had borderline raised PASP values (PASP 35–40 mmHg). An association was found between PH and the number of previous TB episodes, with each additional episode of TB increasing the odds of PH‐postTB 2.13‐fold (confidence interval [CI]: 1.17–3.88; p = 0.013). All of those found to have PH were smokers or ex‐smokers yielding an unadjusted odds ratio for PH‐postTB of 3.67 (95% CI: 0.77–17.46). There was no statistical difference in spirometry or 6MWD, between those with and without PH. Neither symptoms nor co‐morbidities demonstrated significant association with PH. PH after TB was a common finding in this community‐based population. Further research is needed to confirm and determine the significance of these findings.

Funder

Universiteit Stellenbosch

Public Health Research Programme

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Reference44 articles.

1. A global view of pulmonary hypertension

2. Increasing incidence and prevalence of World Health Organization Groups 1 to 4 pulmonary hypertension: a population‐based cohort study in Ontario, Canada;Thiwanka Wijeratne D;Circ Cardiovasc Qual Outcomes,2018

3. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort

4. Pulmonary hypertension: the unaddressed global health burden

5. Heart and Lung Disease review series

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3